MICHAEL MILANO: Open Payments
NPI 1316665862 · ST AUGUSTINE, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$648 in 31 payments from 13 companies in 2025. Trend: 2023 $102 · 2024 $711 · 2025 $648
Food & beverage: $648
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC | 6 | $114 |
| AstraZeneca Pharmaceuticals LP | 4 | $76 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $73 |
| Amgen Inc. | 4 | $72 |
| Novo Nordisk Inc | 3 | $58 |
| ABBVIE INC. | 2 | $51 |
| Averitas Pharma Inc. | 1 | $46 |
| Vanda Pharmaceuticals Inc. | 2 | $39 |
| Exact Sciences Corporation | 2 | $33 |
| UCB, Inc. | 1 | $26 |
Products named: MOUNJARO, CAPLYTA, Ozempic, BREZTRI, OTEZLA, MAVYRET, QUTENZA, FANAPT.
Industry payments across FL — which companies pay providers there.
